Serum EGFR in patients with non-small cell lung cancer (NSCLC) treated with gefitinib

被引：0
作者：
Spreafico, A
Gregorc, V
Ludovini, V
Pistola, L
Amoroso, M
Tofanetti, F
Compagnoni, A
Aondio, G
Tonato, M
Villa, E
机构：
[1] San Raffaele Sci Inst, Div Oncol, I-20132 Milan, Italy
[2] Monteluce Policlin, Dept Med Oncol, Perugia, Italy
[3] Ist Mario Negri, Biometry Unit, Dept Oncol, Milan, Italy
[4] Morigga Pelascini Hosp, Div Med Oncol, Gravedona, Italy
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80490-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S112 / S113
页数：2
相关论文
共 50 条
[31]   EGFR mutation and EGFR intron-1 polymorphism predict gefitinib activity in advanced non-small cell lung cancer (NSCLC) [J].
Franciosi, V. ;
Tiseo, M. ;
De Palma, G. ;
Loprevite, M. ;
Chiaramondia, M. ;
Rindi, G. ;
Naldi, N. ;
Bozzetti, C. ;
Camisa, R. ;
Ardizzoni, A. .
ANNALS OF ONCOLOGY, 2006, 17 :218-218
[32]   First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib [J].
Moiseyenko, V. ;
Procenko, S. A. ;
Levchenko, E. V. ;
Barchuk, A. S. ;
Matsko, D. E. ;
Moiseyenko, F. V. ;
Ivantsov, A. O. ;
Iyevleva, A. G. ;
Mitiushkina, N. V. ;
Imyanitov, E. N. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[33]   Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors [J].
Benesova, Lucie ;
Minarik, Marek ;
Jancarikova, Dana ;
Belsanova, Barbora ;
Pesek, Milos .
ANTICANCER RESEARCH, 2010, 30 (05) :1667-1671
[34]   PROTEOMIC SIGNATURE TO IMPROVE OUTCOME IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH EGFR-TKIS [J].
Lazzari, Chiara ;
Gregorc, Vanesa ;
Spreafico, Anna ;
Vigano, Mariagrazia ;
Milan, Enrico ;
Bachi, Angela ;
D'Amato, Alfonsina ;
Sorlini, Cristina ;
Roca, Elisa ;
Villa, Eugenio .
ANNALS OF ONCOLOGY, 2009, 20
[35]   Clinical factors affecting the late resistance to gefitinib in patients with non-small cell lung cancer (NSCLC). [J].
Segawa, Y. ;
Hotta, K. ;
Umemura, S. ;
Fujiwara, Y. ;
Shinkai, T. ;
Ueoka, H. ;
Takigawa, N. ;
Tabata, M. ;
Kiura, K. ;
Tanimoto, M. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :411S-411S
[36]   A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC) [J].
Kim, Se Hyun ;
Shim, Hyo Sup ;
Cho, Jaeho ;
Jeong, Jae Heon ;
Kim, Sun Mi ;
Hong, Yun Kyoung ;
Sung, Ji Hee ;
Ha, Sang-Jun ;
Kim, Hye Ryun ;
Chang, Hyun ;
Kim, Joo Hang ;
Tania, Crombet ;
Cho, Byoung Chul .
LUNG CANCER, 2013, 79 (03) :270-275
[37]   The results of the treatment with gefitinib (Iressa) in 89 patients with advanced non-small cell lung cancer (NSCLC) [J].
Skrickova, J ;
Tomiskova, M ;
Svobodnik, A ;
Kaplanova, J ;
Kadlec, B ;
Palkova, I ;
Babickova, L ;
Stratil, D ;
Nebesky, T .
LUNG CANCER, 2005, 49 :S376-S376
[38]   A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). [J].
Kim, Han Sang ;
Cho, Byoung Chul .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[39]   Optimum timing of gefitinib therapy in metastatic non-small cell lung cancer (NSCLC) patients. [J].
Ayllon, J ;
Plazanet, V ;
Guillevin, EF ;
Banu, E ;
Bonan, B ;
Oudard, S ;
Barthes, FP ;
Theou, N ;
Sors, H ;
Andrieu, JM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :700S-700S
[40]   EGFR mutations and gefitinib sensitivity in patients with metastatic non-squamous non-small cell lung cancer [J].
Moiseyenko, V. ;
Imyanitov, E. ;
Levchenko, E. ;
Procenko, S. ;
Orlova, R. ;
Iyevleva, A. ;
Buslov, K. ;
Ulibina, Y. ;
Matsko, D. ;
Moiseyenko, F. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345